{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:34:17Z","timestamp":1789526057484,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ejca.2023.03.017","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T13:22:19Z","timestamp":1679491339000},"page":"142-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: A need to review dose"],"prefix":"10.1016","volume":"186","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9713-179X","authenticated-orcid":false,"given":"Vikas","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharath B","family":"Gangadharaiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Upadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adarsh","family":"Barwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekta","family":"Dhamija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivanand","family":"Gamangatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.03.017_bib1","unstructured":"IARC Publications Website\u00a0\u2013\u00a0WHO classification of tumours [Internet]. [cited\u00a02021\u00a0Feb 8]. Available from:\u00a0\u3008https:\/\/publications.iarc.fr\/Book-And-Report-Series\/Who-Classification-Of-Tumours\u3009."},{"key":"10.1016\/j.ejca.2023.03.017_bib2","first-page":"125","article-title":"Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: a nationwide prospective cohort from the French Sarcoma Group","volume":"83","author":"Penel","year":"2017","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"10","key":"10.1016\/j.ejca.2023.03.017_bib3","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1093\/annonc\/mdx323","article-title":"An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)\/Soft Tissue and Bone Sarcoma Group (STBSG)","volume":"28","author":"Kasper","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2023.03.017_bib4","first-page":"428","article-title":"Evaluation of the long term outcome of patients with extremity desmoids","volume":"30","author":"Chew","year":"2004","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc\u00a0Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2023.03.017_bib5","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.hoc.2013.07.008","article-title":"Desmoid tumors: a comprehensive review of the evolving biology, unpredictable behavior, and myriad of management options","volume":"27","author":"Devata","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"issue":"10","key":"10.1016\/j.ejca.2023.03.017_bib6","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1093\/annonc\/mdx323","article-title":"An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)\/Soft Tissue and Bone Sarcoma Group (STBSG)","volume":"28","author":"Kasper","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2023.03.017_bib7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejca.2016.02.008","article-title":"Management of desmoid tumours: a nationwide survey of labelled reference centre networks in France","volume":"58","author":"Penel","year":"2016","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2023.03.017_bib8","first-page":"1310","article-title":"Desmoid tumours in the surveillance era: what are the remaining indications for surgery?","volume":"46","author":"Improta","year":"2020","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"10.1016\/j.ejca.2023.03.017_bib9","first-page":"96","article-title":"The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients","volume":"127","year":"2020","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"13","key":"10.1016\/j.ejca.2023.03.017_bib10","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1245\/s10434-019-07826-6","article-title":"Outcome of\u00a0primary desmoid tumors at all anatomic locations initially managed with active surveillance","volume":"26","author":"van Houdt","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2023.03.017_bib11","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00280-009-1010-0","article-title":"Response of imatinib-resistant extra-abdominal aggressive fibromatosis to sunitinib: case report and review of the literature on response to tyrosine kinase inhibitors","volume":"64","author":"Skubitz","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"issue":"19","key":"10.1016\/j.ejca.2023.03.017_bib12","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.1158\/1078-0432.CCR-10-1177","article-title":"Efficacy of imatinib in aggressive fibromatosis: results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial","volume":"16","author":"Chugh","year":"2010","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"25","key":"10.1016\/j.ejca.2023.03.017_bib13","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1805052","article-title":"Sorafenib for advanced and refractory desmoid tumors","volume":"379","author":"Gounder","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2023.03.017_bib14","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S1470-2045(19)30276-1","article-title":"Pazopanib or methotrexate\u2013vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study","volume":"20","author":"Toulmonde","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.03.017_bib15","unstructured":"Stata 14 | Stata [Internet]. [cited\u00a02021\u00a0Feb 15]. Available from:\u00a0\u3008https:\/\/www.stata.com\/stata14\/\u3009."},{"issue":"12","key":"10.1016\/j.ejca.2023.03.017_bib16","first-page":"10089","article-title":"Health-related quality of life (HRQoL), anxiety, and depression in patients with desmoid type fibromatosis","volume":"30","author":"Garg","year":"2022","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2023.03.017_bib17","first-page":"326","article-title":"Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors","volume":"6","author":"Paksoy","year":"2022","journal-title":"Eurasian J Med Investig"},{"issue":"2","key":"10.1016\/j.ejca.2023.03.017_bib18","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/02841860701765675","article-title":"Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis","volume":"47","author":"Chu","year":"2008","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2023.03.017_bib19","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/cncr.27705","article-title":"Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma","volume":"119","author":"Lee","year":"2013","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2023.03.017_bib20","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4103\/ijc.IJC_105_18","article-title":"Pazopanib efficacy and toxicity in a metastatic sarcoma cohort: are Indian patients different?","volume":"56","author":"Sharma","year":"2019","journal-title":"Indian J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2023.03.017_bib21","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1634\/theoncologist.12-4-426","article-title":"Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors","volume":"12","author":"Strumberg","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2023.03.017_bib22","doi-asserted-by":"crossref","first-page":"S1435","DOI":"10.1016\/j.annonc.2022.08.075","article-title":"LBA2 DeFi: a phase III, randomized controlled trial of nirogacestat versus placebo for progressing desmoid tumors (DT)","volume":"33","author":"Kasper","year":"2022","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923001533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923001533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:40:06Z","timestamp":1760733606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923001533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":22,"alternative-id":["S0959804923001533"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.03.017","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: A need to review dose","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}